Clinical trial
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
NCT00234858 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00234858 |
|---|---|
| Title | Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) |
| Official title | A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome |
| Acronym | STAR |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | trandolapril/verapamil, (Hyzaar) losartan/hydrochlorothiazide |
| Enrollment | 280 |
| Start date | Mar 1, 2004 |
| Primary completion | Apr 1, 2006 |
| First posted | Oct 10, 2005 |
| Last update posted | Jul 15, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: